All In Biotech

Drug Trial Radar · NCT05577416

A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma

A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma

Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Oct 11, 2022

Primary completion

Mar 26, 2025

Study completion Mar 26, 2025

Sponsor

Lead sponsor
Melbourne HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Walter and Eliza Hall Institute of Medical Research; Nuvation Bio Inc.
First posted
Oct 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this clinical trial is to evaluate the feasibility of undertaking a Phase 0 surgical study in patients with diagnosis of a IDH1 mutated Low Grade Glioma (LGG) who have not received prior radiation or chemotherapy and are planned to undergo surgical resection.

Conditions

  • Glioma

Interventions

  • BiopsyProcedure

    Patients will undergo stereotactic biopsy by craniotomy or burr hole.

  • Part A: Safusidenib ErbumineDrug

    Part A: Safusidenib Erbumine orally 250 mg BID for 28 days.

  • Surgery (maximal resection)Procedure

    Surgery: Maximal safe resection, within 24 hours of last dose of Safusidenib Erbumine.

  • Part B: Safusidenib ErbumineDrug

    Part B: Safusidenib Erbumine orally 250 mg BID for 28 days for a minimum of 12, 28-day cycles subject to ongoing documented evidence of clinical benefit, until disease progression or unacceptable toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 0: Feasibility of Phase 0 study in patient populationTime frame: 14 months
  2. Phase 0: pharmacokinetic analysis of tumour tissueTime frame: 4 weeks
  3. Phase 0: pharmacokinetic analysis of cerebrospinal fluid (CSF)Time frame: 4 weeks
  4. Phase 2: Number of Adverse eventsTime frame: up to 30 days after last study dose
  5. Phase 2: Incidence of drug related adverse eventsTime frame: up to 30 days after last study dose
  6. Phase 2: Incidence of dose limiting toxicityTime frame: up to 30 days after last study dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Royal Melbourne Hospital

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.